Who Generates Higher Gross Profit? Viatris Inc. or BioMarin Pharmaceutical Inc.

A Tale of Two Giants: Viatris Inc. vs. BioMarin Pharmaceutical Inc.

In the competitive landscape of the pharmaceutical industry, understanding who leads in generating gross profit can offer valuable insights. From 2014 to 2023, Viatris Inc. consistently outperformed BioMarin Pharmaceutical Inc. in terms of gross profit. Viatris Inc. demonstrated a robust growth trajectory, with its gross profit peaking at approximately $6.44 billion in 2023, marking a significant increase from $3.67 billion in 2014. This represents a growth of over 75% over the decade.

Conversely, BioMarin Pharmaceutical Inc. also showed a positive trend, albeit at a slower pace. Starting at $621 million in 2014, BioMarin's gross profit reached $1.84 billion by 2023, reflecting a growth of nearly 196%. Despite this impressive growth rate, BioMarin's absolute figures remain substantially lower than those of Viatris. This data highlights the dynamic nature of the pharmaceutical sector and the varying strategies companies employ to enhance profitability.